Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
Federal Trade Commission
Argus Health
QuintilesIMS
Healthtrust
Chubb
AstraZeneca
Express Scripts

Generated: January 17, 2018

DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-nine approved drugs.

There are one hundred and three US patents protecting BOEHRINGER INGELHEIM drugs and there have been four Paragraph IV challenges on BOEHRINGER INGELHEIM drugs in the past three years. There is one tentative approval on BOEHRINGER INGELHEIM drugs.

There are two thousand four hundred and eighty patent family members on BOEHRINGER INGELHEIM drugs in sixty-eight countries and one hundred and eighty-one supplementary protection certificates in fifteen countries.

Summary for BOEHRINGER INGELHEIM
International Patents:2480
US Patents:103
Tradenames:40
Ingredients:30
NDAs:49

Drugs and US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim JARDIANCE empagliflozin TABLET;ORAL 204629-002 Aug 1, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim SYNJARDY XR empagliflozin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208658-004 Dec 9, 2016 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-001 May 27, 2016 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim SPIRIVA tiotropium bromide POWDER;INHALATION 021395-001 Jan 30, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim SPIRIVA RESPIMAT tiotropium bromide SPRAY, METERED;INHALATION 021936-001 Sep 24, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim GILOTRIF afatinib dimaleate TABLET;ORAL 201292-002 Jul 12, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-004 Jul 1, 1997 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for BOEHRINGER INGELHEIM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-003 Jul 1, 1997 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim COMBIPRES chlorthalidone; clonidine hydrochloride TABLET;ORAL 017503-001 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim COMBIPRES chlorthalidone; clonidine hydrochloride TABLET;ORAL 017503-002 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim STRIVERDI RESPIMAT olodaterol hydrochloride SPRAY, METERED;INHALATION 203108-001 Jul 31, 2014 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-003 Jul 1, 1997 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim COMBIVENT RESPIMAT albuterol sulfate; ipratropium bromide SPRAY, METERED;INHALATION 021747-001 Oct 7, 2011 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim CATAPRES clonidine hydrochloride TABLET;ORAL 017407-003 Approved Prior to Jan 1, 1982 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim JENTADUETO XR linagliptin; metformin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208026-002 May 27, 2016 ➤ Subscribe ➤ Subscribe
Boehringer Ingelheim COMBIPRES chlorthalidone; clonidine hydrochloride TABLET;ORAL 017503-003 Apr 10, 1984 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 20 mg, 30 mg and 40 mg ➤ Subscribe 7/12/2017
➤ Subscribe Capsules eq. to 110 mg base ➤ Subscribe 12/15/2015
➤ Subscribe Tablets 5 mg ➤ Subscribe 5/4/2015
➤ Subscribe Tablets 2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg ➤ Subscribe 5/4/2015
➤ Subscribe Capsules eq. to 75 mg base and 150 mg base ➤ Subscribe 10/20/2014
➤ Subscribe Extended-release Tablets 400 mg ➤ Subscribe 6/21/2013
➤ Subscribe Extended-release Tablets 2.25 mg and 3.75 mg ➤ Subscribe 7/26/2011
➤ Subscribe Extended-release Tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg ➤ Subscribe 6/1/2010
➤ Subscribe Oral Suspension 7.5 mg/5 mL ➤ Subscribe 12/17/2009
➤ Subscribe Tablets 80 mg/25 mg ➤ Subscribe 2/27/2009
➤ Subscribe Tablets 80 mg/12.5 mg and 40 mg/12.5 mg ➤ Subscribe 12/31/2008
➤ Subscribe Tablets 0.75 mg ➤ Subscribe 7/31/2008
➤ Subscribe Extended-release Capsules 25 mg and 200 mg ➤ Subscribe 2/1/2007
➤ Subscribe Tablets 20 mg, 40 mg and 80 mg ➤ Subscribe 12/26/2006
➤ Subscribe Tablets 0.125 mg, 0.5 mg, 1 mg and 1.5 mg ➤ Subscribe 6/24/2005
➤ Subscribe Tablets 0.25 mg ➤ Subscribe 5/27/2005
➤ Subscribe Capsules 0.4 mg ➤ Subscribe 12/20/2004

Non-Orange Book US Patents for BOEHRINGER INGELHEIM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,751,855 Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines ➤ Subscribe
5,911,851 Atomizing nozzle and filter and spray generating device ➤ Subscribe
8,404,697 Quinazoline derivatives for the treatment of cancer diseases ➤ Subscribe
6,414,008 Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions ➤ Subscribe
7,019,012 Quinazoline derivatives and pharmaceutical compositions containing them ➤ Subscribe
6,410,742 Polymorphs of telmisartan ➤ Subscribe
8,318,669 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
6,169,181 Compounds useful to treat retroviral infections ➤ Subscribe
8,513,190 Method of regulating glucose metabolism, and reagents related thereto ➤ Subscribe
6,503,440 Process for making a container with a pressure equalization opening and containers produced accordingly ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for BOEHRINGER INGELHEIM Drugs

Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00030 Denmark ➤ Subscribe PRODUCT NAME: LINAGLIPTIN OG SALTE DERAF; NAT. REG. NO/DATE: EU/1/11/707/001-011 20110830; FIRST REG. NO/DATE: EU EU/1/11/707/001-0011 20110830
C0008 France ➤ Subscribe PRODUCT NAME: VILDAGLIPTINE OU UN DE SES SELS PHARMACETIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/414/001 DU 20070926; REGISTRATION NO/DATE AT EEC: EU/1/07/414/001-017 DU 20070926
128 Luxembourg ➤ Subscribe PRODUCT NAME: 8-(3-AMINOPIPERIDIN-1-YL)-7-BUT-2-INYL-3-METHYL-1-(4-METHYLCHINAZOLIN-2-YLMETHYL)-3, 7-DIHYDROPURIN-2, 6-DION, LES ENANTIOMERES ET LEURS SELS, EN PARTICULIER LA LINAGLIPTINE COMBINEE AVEC DU CHLORHYDRATE DE METFORMINE. LINAGLIPTINE
2005008 Lithuania ➤ Subscribe PRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
90011-2 Sweden ➤ Subscribe PRODUCT NAME: AFATINIB, TAUTOMERER, STEREOISOMERER OCH SALTER DAERAV, FYSIOLOGISKT GODTAGBARA SALTER MED OORGANISKA ELLER ORGANISKA SYROR ELLER BASER, SAERSKILT ETT MALEATSALT DAERAV, MER FOERETRAEDELSEVIS ETT DIMALEATSALT DAERAV; REG. NO/DATE: EU/1/13/879 20130925
00707 Netherlands ➤ Subscribe PRODUCT NAME: SAXAGLIPTIN; REGISTRATION NO/DATE: EU/1/09/545/001-010 20091001
90007 Netherlands ➤ Subscribe PRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT; REGISTRATION NO/DATE: EU/1/98/089/001-EU/1/98/089/010 19981211
C0019 France ➤ Subscribe PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGUSTRATION: CH/LI 54 393 19971223
00216 Netherlands ➤ Subscribe PRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
334 Luxembourg ➤ Subscribe CERTIFICATE TITLE: SITAGLIPTIN, OU UN SEL DE CELUI-CI PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER LE SEL PHOSPHATE (JANUVIA); FIRST REGISTRATION: 20070321
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Teva
Express Scripts
Merck
Dow
Julphar
Cipla
Cerilliant
Mallinckrodt
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot